Yahoo · Sep 10, 2026
McKesson (MCK) Suffers a Larger Drop Than the General Market: Key Insights
McKesson (MCK) closed at $880.86 in the latest trading session, marking a -1.21% move from the prior day.
NYSE · MCK
McKesson Corporation
Healthcare · Medical - Distribution
$899.56
Down-$11.39 (-1.25%)
Updated Sep 16, 2026, 11:11 AM
SID Score
6.9/10
Composite research score
Smart Money
47/100
Neutral
- Market cap
- 101.96B
- P/E ratio
- 32.2
- Dividend yield
- 0.34%
- 52-week range
- $723.68 – $999.00
- Volume
- 1.15M
- Avg. volume
- 896.08K
Price performance
MCK price history
1M range · 20 trading sessions · Daily adjusted prices
MCK closed at $899.56 after 20 trading sessions, up 3.49% for the selected period.
- Last close
- $899.56
- Period change
- +3.49%
- Period low
- $838.75
- Period high
- $924.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $902.31 | $907.4975 | $883.59 | $899.56 | 1.15M |
| Sep 14, 2026 | $900.00 | $912.00 | $893.38 | $910.95 | 619.3K |
| Sep 11, 2026 | $888.37 | $893.92 | $874.31 | $881.51 | 888.81K |
| Sep 10, 2026 | $899.77 | $904.83 | $879.24 | $880.86 | 852.97K |
| Sep 9, 2026 | $889.25 | $897.51 | $880.27 | $891.68 | 972.38K |
| Sep 8, 2026 | $891.45 | $904.505 | $877.53 | $889.12 | 747.85K |
| Sep 4, 2026 | $911.15 | $921.09 | $905.103 | $907.99 | 879.27K |
| Sep 3, 2026 | $924.89 | $929.95 | $916.14 | $921.38 | 816.79K |
| Sep 2, 2026 | $914.29 | $928.49 | $910.655 | $924.78 | 856.56K |
| Sep 1, 2026 | $887.70 | $914.43 | $886.8345 | $906.77 | 787.99K |
| Aug 31, 2026 | $882.83 | $892.80 | $876.482 | $885.32 | 1.38M |
| Aug 28, 2026 | $895.04 | $900.22 | $890.795 | $893.39 | 606.05K |
| Aug 27, 2026 | $889.27 | $891.95 | $880.77 | $890.51 | 1.11M |
| Aug 26, 2026 | $905.54 | $918.00 | $891.9939 | $896.65 | 1.06M |
| Aug 25, 2026 | $871.40 | $905.66 | $869.365 | $905.09 | 882.58K |
| Aug 24, 2026 | $861.47 | $875.64 | $859.75 | $873.79 | 600.5K |
| Aug 21, 2026 | $839.84 | $867.915 | $837.8801 | $858.90 | 1.58M |
| Aug 20, 2026 | $850.00 | $858.68 | $838.71 | $838.75 | 557.69K |
| Aug 19, 2026 | $864.22 | $869.99 | $850.01 | $853.71 | 938.78K |
| Aug 18, 2026 | $870.23 | $886.14 | $867.65 | $869.26 | 618.72K |
Latest MCK news
The latest Smart Investors Daily articles mentioning MCK.
Stock researchCompany · Overview
MCK research
Overview
Company profile and research snapshot.
Company profile
McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $910.40
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | RBC Capital | Sector Perform | — |
| Aug 19, 2026 | Barclays | Overweight | — |
| Aug 19, 2026 | RBC Capital | Sector Perform | — |
| Aug 11, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 6, 2026 | Evercore ISI Group | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 9, 2026
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Yahoo · Sep 9, 2026
Frazier Healthcare Partners Welcomes Tom Rodgers as Senior Partner
SEATTLE, September 09, 2026--Frazier Healthcare Partners, a private equity firm focused exclusively on the healthcare industry, is pleased to announce that Tom Rodgers will join the firm as a Senior Partner in October 2026. In this role, Mr. Rodgers will partner with Frazier’s Growth Buyout deal teams, providing strategic counsel on investment evaluation, portfolio value creation, and sector-level insights informed by more than 35 years of experience in healthcare strategy, corporate development
Yahoo · Sep 8, 2026
Reliant Infusion Names Tommy Pourmahram Chief Executive Officer
CHICAGO, September 08, 2026--Shore Capital Partners ("Shore" or "Shore Capital"), a Chicago-based private equity firm with an office in Nashville, today announced that Tommy Pourmahram has been named Chief Executive Officer of Reliant Infusion, a Shore portfolio company and provider of specialty infusion services.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
